Form 4: DURECT CEO James Brown Reports Share Disposition Post-Merger

DURECT Corporation's President and CEO, James E. Brown, reported the disposition of all his beneficial ownership in common stock and derivative securities following the company's merger with Bausch Health Americas, Inc.

Summary

• DURECT Corporation completed its merger with Bausch Health Americas, Inc. (Parent) and BHC Lyon Merger Sub, Inc. (Purchaser) on September 11, 2025.
• The merger followed a tender offer where DURECT stockholders received $1.75 per share in cash, plus one non-tradeable contingent value right (CVR) per share.
• CVRs represent a contractual right to a pro rata portion of two milestone payments, totaling up to $350,000,000, contingent on specific achievements.
• Following the tender offer, DURECT became a wholly-owned subsidiary of Bausch Health Americas, Inc.
• James E. Brown, President & CEO, disposed of 448,376 direct common shares, 8,000 indirect common shares (held by Brown 2006 Trust), and 96,959 shares from restricted stock units.
• Stock options with an exercise price below $1.75 were accelerated and exercised, with resulting shares treated in the merger.
• Stock options with an exercise price equal to or greater than $1.75 were canceled, with holders becoming eligible for cash retention bonuses tied to net sales milestones.

Sentiment

Score: 7

Explanation: The completion of the merger provides immediate cash value to shareholders and potential future upside through CVRs, indicating a successful exit for DURECT as an independent public entity. The provision for retention bonuses for option holders also suggests a structured transition.

Positives

• Merger completion provides immediate cash value ($1.75 per share) to former DURECT shareholders.
• Contingent Value Rights offer potential for additional future payments up to $350,000,000 based on milestone achievements.
• Option holders with higher exercise prices are eligible for cash retention bonuses, providing an alternative form of compensation.

Negatives

• DURECT Corporation is no longer a publicly traded entity, limiting future public investment opportunities in the company.
• The contingent value rights are non-tradeable, restricting liquidity for potential future value.
• Future payments from CVRs and retention bonuses are uncertain and dependent on the achievement of specific milestones.

Risks

• Achievement of the specified milestones for the contingent value rights and cash retention bonuses is not guaranteed, meaning the full potential value may not be realized.
• The non-tradeable nature of the contingent value rights means shareholders cannot sell their rights for immediate liquidity.

Future Outlook

The future outlook for former DURECT shareholders includes potential additional cash payments from Contingent Value Rights, which are contingent on the achievement of specific milestones. For former option holders with canceled options, eligibility for cash retention bonuses is tied to future net sales milestones.

Industry Context

This transaction represents a consolidation within the pharmaceutical or biotechnology sector, where larger entities like Bausch Health acquire smaller, specialized companies like DURECT, often for their pipeline assets or technology. Such mergers are common strategies for growth and portfolio expansion in the industry.

Management Changes

Corporate Governance

Related Party Transactions

• The merger agreement was executed between DURECT Corporation and Bausch Health Americas, Inc. (Parent), BHC Lyon Merger Sub, Inc. (Purchaser), and Bausch Health Companies Inc. (BHC), representing a transaction with the acquiring entity.

Stakeholder Impact

• Shareholders: Received $1.75 per share in cash and non-tradeable Contingent Value Rights, representing potential future payments.
• Employees (Option Holders): Those with in-the-money options had them accelerated and exercised, while those with out-of-the-money options had them canceled but became eligible for cash retention bonuses.

Next Steps

• Achievement of specified milestones for Contingent Value Rights to trigger additional payments.
• Achievement of certain net sales milestones for former option holders to receive cash retention bonuses.

Key Dates

Keywords

DURECT Corporation, DRRX, Bausch Health Americas, BHC, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Insider Trading, Form 4, James E. Brown, CEO, Beneficial Ownership